[Current status and problems of anticancer drug-induced lung injuries].
Some large-scale clinical investigations on gefitinib-induced lung injury have been performed,which have much new information about anticancer drug-induced lung injuries and indicated significant problems in the development of new anticancer drugs. Analysis of gefitinib-induced lung injury revealed varying patterns of clinical features, ethnic differences in onset, risk factors for development and diagnostic difficulties in anticancer drug-induced lung injuries. Furthermore, we realized again underlying problems in the process of developing new anticancer drugs and the importance of post-marketing surveillance. We must elucidate the mechanism of anticancer drug-induced lung injuries to manage them effectively.